1 in 3 Men Have This. The 8-Week Fix Almost Nobody Has Been Told About.

Approximately 30% of men worldwide have premature ejaculation. Peer-reviewed clinical trials have quietly proven a treatment that works — no drugs, no doctor visits, no partner involvement. A small Korean studio may have finally built the object men will actually use.

Approximately 30% of men worldwide meet the criteria for premature ejaculation. That figure comes from the Global Study of Sexual Attitudes and Behaviors, and it has been stable for over a decade. It is, by every credible measure, the most common sexual dysfunction in men — more prevalent than erectile dysfunction, more prevalent than low libido. It is also, by every credible measure, the one men are least likely to discuss with a doctor.

That silence has been expensive. Because for the past four years, peer-reviewed evidence has been quietly assembling around a treatment approach that requires no medication, no clinic visits, no partner involvement, and no ongoing prescription: device-guided masturbation training.

What the trials actually found.

The most-cited clinical trial is a 2021 multicenter randomized controlled study published in PLoS ONE. Forty men diagnosed with lifelong premature ejaculation were assigned to an 8-week Sphincter Control Training protocol using an electronic silicone sleeve called MYHIXEL. The results: mean intravaginal ejaculatory latency time (IELT) increased by a factor of 4.27. Sixty percent of participants no longer met the diagnostic criteria for PE at the end of the trial. Some men in the trial saw improvements up to 7× their baseline. No side effects were recorded.

A second study, published in 2023 by researchers using the Men’s Training Cup Keep Training — a different silicone masturbation device — replicated the pattern. Eighteen participants, 8 weeks of guided use. Baseline IELT of 103.91 seconds increased to 232.10 seconds. No adverse events.

For context: the current gold-standard pharmaceutical intervention for PE — off-label use of SSRIs like paroxetine or dapoxetine — typically produces IELT improvements in the 2×–3× range, with side effects that include nausea, decreased libido, and dependency risk. The clinical trials on masturbation-based training are, by the numbers, competitive with or superior to the pharmaceutical option, and they carry no drug side-effect profile.

Why nobody’s heard about this.

Two reasons. First, the research is recent — the MYHIXEL trial was 2021, the MTCK trial was 2023, and clinical guidelines lag research by 3–5 years typically. Second, the devices themselves have looked, until now, like medical devices — because that’s what they were designed to be. MYHIXEL retails for approximately $400. It ships in a labeled clinical box. It looks like a small speaker or a wireless charger. In photos, it reads as a therapy device. That’s not incidental — the FDA and equivalent regulators require medical-device positioning for products making clinical claims. But the same positioning that legitimizes the product to a doctor makes it a product a man doesn’t leave on his bathroom shelf.

Where Loma enters the picture.

Loma is a Korean design studio, founded 2020 in Seoul, that makes an entirely different category of object. They don’t sell a medical device. They don’t make clinical claims. Their Candle line is a $38 silicone sleeve, hand-poured in Korea, that comes in nine internal textures — each designed for a different body and preference. And critically for this conversation: the product itself is designed to look like a candle. Cream silicone, pillar shape, sits on a bathroom shelf next to skincare and a hardcover book. Nobody who walks through the room can tell what it is.

The mechanism the MYHIXEL trial validated — slow, controlled use of a silicone sleeve to train ejaculatory awareness — is not proprietary. It’s a principle. The device is the delivery mechanism, not the intellectual property. Any silicone sleeve used with the same protocol produces the same physiological training. What differs across the market is design, cost, and whether the object survives in a real man’s life or ends up in the back of a closet.

Loma has quietly sold 200,000 units of the Candle line in five years. The brand has never run a clinical study — it has never claimed to. What it has claimed, consistently, in its own approved marketing language, is that its product is a “pleasure toy for men, designed to blend in.” What the peer-reviewed research on similar-form-factor devices suggests, separately, is that consistent slow use of that kind of object trains the same physiological reflex that MYHIXEL is FDA-registered to train.

You do the math.